Imaging AI in Massachusetts

Clairity, Inc. is a Boston-based healthcare technology company specializing in artificial intelligence-driven breast cancer risk assessment. The company develops Clairity Breast, the first FDA-authorized AI platform designed to predict a woman's five-year future risk of developing breast cancer using existing screening mammograms. The platform leverages advanced computer vision and machine learning algorithms to identify risk patterns that are not visible to the human eye, enabling earlier detection and prevention opportunities. Clairity Breast integrates seamlessly into existing mammography workflows without requiring additional imaging or specialized hardware, making it accessible to health systems nationwide. The product targets women beginning at age 35 and has been incorporated into updated National Comprehensive Cancer Network (NCCN) clinical guidelines for breast cancer screening and risk assessment. The company emphasizes equitable risk assessment to improve access to life-saving early detection and prevention strategies across diverse populations. Clairity's regulatory credentials include FDA authorization for its AI diagnostic platform. The company is in a pre-launch phase, partnering with health systems across the United States to implement the solution in clinical settings.

QMENTA is a cloud-based medical imaging AI platform founded in 2013 that specializes in neuroimaging data management, processing, visualization, and analysis for clinical trials, research, and diagnostic support. The platform serves biopharmaceutical companies, CROs, medical device manufacturers, academic institutions, and diagnostic centers. QMENTA's integrated infrastructure includes Smart Uploader with HIPAA-compliant PHI de-identification, secure cloud PACS connectivity with automated workflows, over 50 AI-powered imaging biomarkers, Central Review capabilities for remote collaboration, and an Imaging Management System with EDC and query management tools. The company has processed 13M+ imaging scans for 1M+ study participants across 250+ connected sites and completed 1M+ AI imaging analyses. Solutions address neurological diseases, oncology, and rare disease diagnostics with demonstrated cost reductions (50%) and reading time improvements (75%).

PathAI is an AI-driven digital pathology company providing cloud-native software solutions for anatomic pathology laboratories, biopharma organizations, and clinical research. The company specializes in AI-powered histopathology analysis and digital pathology workflow management. PathAI's flagship platform, AISight®, is a cloud-native, open-architecture enterprise solution that integrates case management, image management, and AI-based diagnostic tools to enable multiple histopathology use cases. The platform serves as a central hub for digital pathology workflows across academic medical centers, reference laboratories, and health systems. AISight® Dx received FDA clearance for primary diagnosis in June 2025. PathAI also offers specialized AI-assisted tools including AIM-MASH (FDA-qualified for metabolic-associated fatty liver disease clinical trials) and AIM-HI UC/IBDExplore for standardized histopathology endpoints in clinical trials. The company operates a proprietary pathologist contributor network of board-certified pathologists to support algorithm training and validation, with millions of annotations contributed. Services include BioPharma solutions for drug and diagnostic development, central laboratory operations, and anatomic pathology lab solutions. Notable partnerships include expanded collaboration with Labcorp to deploy FDA-cleared digital pathology nationwide. The company combines pathology domain expertise with machine learning to advance precision medicine, biomarker discovery, and clinical trial standardization.

Ontact Health Co., Ltd. develops SONIX Health, an FDA-cleared (510(k) K240645) AI-powered echocardiography analysis workstation designed to automate cardiac ultrasound interpretation and measurement. The solution performs fully automated analysis of 81 diagnostic parameters with 98% image recognition accuracy and 91% measurement accuracy, eliminating the need for ECG input by automatically detecting heart cycles via valve motion analysis. SONIX Health operates as vendor-neutral software compatible with multi-vendor echocardiography equipment, deployable on-premise or cloud-based without requiring high-specification hardware. The platform streamlines workflow through one-touch analysis from imaging to report generation, reducing clinician workload and examination wait times while supporting training applications. The company emphasizes clinical validation through peer-reviewed publications in cardiovascular imaging journals and demonstrated deployment in hospital environments across multiple geographies. Target markets include cardiac diagnostic centers, hospital ultrasound departments, and training programs seeking to standardize and accelerate echocardiographic assessment.

Sonio is a cloud-based AI-powered ultrasound reporting software platform specializing in OB-GYN and prenatal care. The platform integrates with ultrasound machines from all manufacturers to deliver FDA-cleared and CE-marked AI diagnostics, quality control, and automated reporting workflows. Key capabilities include Sonio Detect (AI-assisted anomaly detection), automated image management with intelligent view sorting, real-time quality control verification, visual checklists for exam completeness, integrated practice analytics, and seamless connectivity to EHRs, PACS, billing systems, and external providers via HL7/FHIR/eFAX. The platform enables sonographers and OB-GYNs to standardize reporting, improve diagnostic accuracy, reduce manual data entry, and enhance prenatal care access globally. Sonio operates on secure cloud or on-premise infrastructure with SOC2 Type II, HIPAA, ISO 13485, and GDPR compliance.

Cercare Medical A/S is a Denmark-based medical imaging software company specializing in advanced perfusion and metabolic imaging solutions for neurological and oncological applications. Founded in 2001 by Professor Kim Beuschau Mouridsen and PhD Mikkel Bo Hansen, the company develops automated, on-premise perfusion imaging software compatible with any MRI and CT scanner platform. Cercare Perfusion software generates unique biomarker maps including Capillary Transit-Time Heterogeneity (CTH), Oxygen Extraction Fraction (OEF), Cerebral Metabolic Rate of Oxygen (CMRO₂), relative Cerebral Blood Volume (rCBV), relative Cerebral Blood Flow (rCBF), and Mean Transit Time (MTT). Clinical applications include acute ischemic stroke assessment, brain tumor characterization and grading, neurodegenerative disease monitoring, and oncology applications. The Cercare Medical Neurosuite (CMN) integrates AI-enabled modules for automated detection and segmentation of hypoperfusion and ischemic core regions. The company's CBCT (cone-beam CT) perfusion capability provides real-time analysis in angiography suites, enabling direct-to-angio workflows and post-intervention assessment. Cercare operates globally with authorized distribution partners including Siemens, Terabox, AIDOC, VIZ, Sectra, and Microsoft, serving hospitals in multiple countries with over 1 million annual diagnoses supported. The software is vendor-agnostic, operates on-premise with no cloud dependency, and is designed for stroke, oncology, Alzheimer's disease, dementia, and neoplasia applications.

Momentum Health Inc. develops Momentum Spine, a radiation-free 3D digital spine monitoring platform that uses smartphone video capture to create clinical-grade 3D spine scans and AI-powered analytics. The platform enables remote monitoring of complex spine conditions—particularly pediatric scoliosis (AIS) and adult spinal deformity—without requiring in-person X-rays or imaging center visits. The system employs deep-learning models to predict Cobb Angle (mean absolute error ~5–6°, comparable to inter-observer radiologist variation), track spinal asymmetry, assess brace compliance, analyze dynamic gait and posture metrics, and monitor whole-body sagittal alignment. Patients perform 45-second smartphone scans at home; clinicians access a secure web dashboard for real-time remote monitoring, triage, and data-driven intervention planning. Momentum Spine integrates into clinical workflows and supports Remote Therapeutic Monitoring (RTM) billing models. The company holds FDA 510(k) clearance (K232023, product code LDK) for the US market and Canadian Medical Device Establishment License (MDEL) clearance. The platform is SOC 2 Type 2 certified, HIPAA and PIPEDA compliant, and maintains ISO 13485 quality certification. Target markets include spine centers, hospital networks, pediatric orthopedic clinics, and research institutions. The company is based in Montreal, Canada, and serves leading healthcare systems including UCSF, NYP Och Spine, Cedars-Sinai, and Children's Hospital Los Angeles.

Butterfly Network manufactures and distributes the iQ3, a handheld, whole-body portable ultrasound probe for point-of-care ultrasound (POCUS) applications. The iQ3 integrates advanced AI-powered diagnostic capabilities, workflow management software, and a comprehensive education suite to enable clinicians across emergency medicine, primary care, obstetrics, and specialty practices to perform real-time ultrasound assessments at the bedside or point of care. The company serves individual practitioners, health systems, hospitals, and medical education institutions. Products include the iQ3 probe (FDA-cleared), with an established installed base of 145,000+ customers globally. The iQ3 represents an upgrade path from earlier Butterfly models (iQ, iQ+); trade-in programs are offered. Key software platform: Compass AI, a POCUS management module designed to centralize ultrasound workflows across health systems. Clinical applications include obstetric gestational age assessment, lung ultrasound (B-line detection), cardiac evaluation, and emergency diagnostic imaging. The company publishes clinical evidence demonstrating impact on patient outcomes, including reduced length of stay and improved charge capture in hospital deployments. Regulatory credentials include FDA 510(k) clearance. The platform emphasizes ease of use, portability, and seamless integration into clinical workflows for both resource-constrained and academic medical environments.

Overjet is a dental AI software company providing an integrated platform for clinical decision support and administrative automation. The company develops FDA-cleared vision AI for x-ray analysis that detects disease and anatomical structures to improve diagnosis and case acceptance. Core products include Vision AI (x-ray analysis software), IRIS (AI-native dental imaging software with auto-populated templates and image enhancement), Dental Insurance Verification (automated coverage verification across 300+ payers with code-level breakdowns), and Voice AI Suite (unified clinical intelligence combining imaging insights with voice-to-text documentation and automated charting). The platform serves dentists, dental service organizations (DSOs), educators, and dental insurers. Overjet's technology streamlines clinical workflows, reduces administrative burden through automated insurance verification and charting, and improves patient understanding through AI visualizations. The company is trusted by major dental organizations including Dental Care Alliance, CoreDental, Jefferson Dental, Aligned Dental Partners, and others. Products integrate with existing dental practice management systems and consolidate imaging and AI capabilities without separate cloud storage fees. Regulatory clearance includes FDA approval for vision AI diagnostic capabilities.

Activ Surgical is a Boston-based digital surgery company specializing in hardware-agnostic surgical software and intraoperative imaging technologies designed to enhance visualization and reduce surgical errors. The company's flagship product, ActivSight™ Intelligent Light, is FDA-cleared and integrates with existing laparoscopic and robotic surgical systems to provide real-time visualization of blood flow and tissue perfusion. ActivSight offers surgeons critical physiological insights invisible to the naked eye through dye-free ActivPerfusion™ and ActivICG™ imaging modes. The patent-protected ActiveEdge™ platform leverages augmented reality, artificial intelligence, and machine learning to improve intraoperative decision-making and address preventable surgical complications. Activ Surgical has achieved significant milestones including the world's first autonomous robotic surgery of soft tissue and CE Mark approval. With $87.5 million in funding, the company operates pilot sites in major U.S. hospital networks, addressing the critical clinical need that preventable surgical errors contribute to over 400,000 deaths annually in the U.S.

VUNO Med, Inc. develops AI-driven diagnostic and patient monitoring software solutions for healthcare providers. The company manufactures two principal FDA-cleared products: VUNO Med®-DeepCARS®, an early warning system for cardiac arrest risk assessment in general ward inpatients using vital signs monitoring (heart rate, blood pressure, respiratory rate, oxygen saturation, plus age and timing); and VUNO Med®-Chest X-ray™ Triage, an AI-based diagnostic support system for detecting suspected chest abnormalities and major pulmonary diseases from chest radiography. Both products integrate deep learning algorithms with clinical workflows to assist healthcare professionals in reducing response times, lowering clinical costs, and improving patient outcomes. The DeepCARS system has been prospectively validated in multicentre studies published in peer-reviewed journals including Critical Care Medicine and Resuscitation, demonstrating predictive value for in-hospital cardiac arrest and unplanned ICU transfer. The Chest X-ray Triage system has undergone external validation for detection of nodular and reticular opacities in interstitial lung disease and other pulmonary conditions. VUNO distributes its solutions primarily to hospitals and health systems in the United States and maintains clinical advisory relationships with leading academic medical centers. The company emphasizes regulatory compliance and clinical evidence to support adoption in acute care settings.

BrainSpec, Inc develops a cloud-based software platform for Magnetic Resonance Spectroscopy (MRS) analysis. The platform provides non-invasive 'virtual biopsy' capability by measuring brain metabolite concentrations at precision levels 10,000 times lower than conventional MRI. BrainSpec Core™ combines a linear combinations model post-processing backend with a user-friendly web interface for clinicians and researchers. The platform supports cross-vendor MRI compatibility, enables precision metabolite measurement, and provides automated reporting with cloud-based processing to ensure access to cutting-edge analytical algorithms. Applications include assessment of brain tumors, Alzheimer's disease, Multiple Sclerosis, and other neurological conditions. The company has developed proprietary reference databases of normal and diseased brain chemistry to streamline MRS interpretation to clinical utility standards comparable to routine blood testing. The platform is currently in the pre-market stage with FDA clearance pending. The company is accepting a limited number of pilot research sites. Over 28,000 publications document clinical applications of MRS technology.

Body Vision Medical is a commercial-stage medical device company specializing in AI-powered imaging solutions for lung cancer detection and intervention. The company's flagship product, the LungVision® system, transforms standard 2D C-arm X-ray images into advanced 3D intraoperative imaging for enhanced navigation during endobronchial biopsies. Utilizing proprietary AI Tomo® technology, LungVision corrects for CT-to-body divergence and enables tool-in-lesion confirmation, improving diagnostic yield from traditional 55-75% to approximately 90-95% for small pulmonary lesions. The system delivers superior economics with lower total cost of ownership than robotic alternatives, reduced radiation exposure (1/5 of 3D C-arms), and accessibility worldwide. Founded in 2014 by engineers experienced in electromagnetic navigation bronchoscopy, Body Vision empowers pulmonologists and thoracic surgeons with real-time, high-precision navigation for biopsy and localized therapy delivery. Recognized as a Top Medtech Startup in 2023.

Anumana Inc. is a cardiovascular AI software company headquartered in Cambridge, MA, developing FDA-cleared algorithms for ECG analysis and cardiac disease detection. Founded in 2021 as a joint effort between Mayo Clinic and nference, the company specializes in ECG-AI®, a proprietary platform that analyzes 12-lead electrocardiograms using deep learning to identify cardiac pathology invisible to clinicians. The flagship algorithm detects low ejection fraction (LEF) and is clinically validated on approximately 2.9 million ECG-echo pairs from 676,000+ patients across diverse populations. The platform has received FDA 510(k) clearance (K250652) for LEF detection and recent clearances for cardiac amyloidosis and pulmonary hypertension algorithms. Anumana's technology integrates seamlessly into existing EHR systems and ECG management platforms without requiring external data processing—algorithms run on-premises for enhanced data security and privacy. The company's AI engine processes 60,000 ECG data points per study and delivers clinical findings compatible with current cardiology workflow. Product portfolio includes multiple cardiac-focused algorithms in development spanning early disease detection, perioperative imaging, atrial fibrillation risk stratification, hyperkalemia detection, diastolic dysfunction assessment, and cardiomyopathy screening. Clinical evidence published across 100+ peer-reviewed publications in journals including Nature Medicine, JACC, and European Heart Journal. The platform supports EHR orderable creation, HL7 configuration, CPT code assignment, and is eligible for reimbursement in US and EU markets. Anumana serves cardiology practices, hospitals, and integrated health systems seeking AI-assisted ECG interpretation and early identification of at-risk cardiac patients.

Angiowave Imaging develops AngioWaveNet™, a post-processing artificial intelligence platform designed for fluoroscopic angiography systems in cardiac catheterization laboratories. The software processes unprocessed angiographic cines in DICOM XA format from any traditional imaging system to enhance vasculature visualization and facilitate clinical diagnosis, particularly in patients with coronary artery disease. AngioWaveNet™ is compatible with existing fluoroscopic angiography infrastructure without requiring hardware modifications. The technology addresses a clinical need in image interpretation for coronary interventions, peripheral artery disease evaluation, stroke clot retrieval procedures, angioplasty and stent guidance, cardiac valve procedures, and electrophysiology applications. As a post-processing solution, the platform operates across diverse imaging systems in catheterization labs, trauma centers, and neurology departments. The company positions its AI-driven approach as an innovation in a mature technology segment that has experienced limited advancement over the past two decades. Angiowave offers free trial access and direct angiogram processing services through their web platform.

DeepHealth is a global leader in AI-powered health informatics and radiology solutions, headquartered in Somerville, Massachusetts and operating as a subsidiary of RadNet, Inc. Founded in 2015, the company develops cloud-native platforms that integrate diagnostic imaging tools with advanced artificial intelligence to enhance clinical workflows and patient outcomes. DeepHealth OS, the company's core cloud-native operating system, unifies enterprise data and provides AI-driven insights tailored for radiologists and care teams. The platform supports detection, assessment, and monitoring across multiple imaging modalities. Key clinical AI solutions include breast cancer screening (Breast Suite with ProFound Pro and Safeguard Review), lung cancer management, prostate health, and brain health diagnostics. DeepHealth's remote scanning capability (TechLive™) enables multimodality, vendor-agnostic imaging delivery. The company serves over 300 screening sites globally and processes more than 15 million annual exams across the U.S. and Europe. Recent strategic acquisitions of Gleamer, CIMAR UK, and Alpha RT assets have expanded DeepHealth's portfolio in clinical AI, image management, and remote staffing services.

NeuroSync develops objective, AI-powered digital health solutions for brain health assessment and performance optimization. The company's flagship product, EYE-SYNC, is an FDA-cleared platform that delivers rapid, portable eye-tracking and oculomotor testing for concussion diagnosis, neuro health evaluation, and performance monitoring. The platform comprises XR (extended reality) hardware, proprietary software with AI analytics, and customizable clinical reporting. Assessments complete in under one minute with 0.9 test-retest reliability, leveraging validated proprietary algorithms and quantification methods. NeuroSync serves healthcare systems, clinical research organizations, sports medicine programs, military/active duty personnel, and biopharma CNS trials. The platform is deployed at leading academic medical centers (Massachusetts General Hospital, Texas Health, Houston Methodist), collegiate athletic programs (Rice University, Georgia Tech, Virginia Tech), specialty neurology clinics, vestibular therapy centers, and professional sports organizations. Solutions address the gap in objective diagnostics for neurological conditions affecting over 83 million Americans annually. The wireless, portable design enables deployment in clinical, research, athletic, and field settings. NeuroSync markets to clinicians, researchers, high-performance specialists, and military medical personnel seeking objective, rapid brain health metrics for diagnosis, monitoring, and therapeutic planning.

MetaSystems International GmbH is a global developer and manufacturer of automated microscopy system software and hardware, headquartered in Germany with operations established since 1986. The company serves clinical laboratories and research institutions across 103 countries with solutions for automated image capture, analysis, and workflow management in cytology and pathology applications. Primary product lines include the Metafer automated microscopy platform with AI-enabled imaging modules (sperm detection, forensic casework support) and the Ikaros image analysis system. MetaSystems also maintains a separate Probes division (MetaSystems Probes GmbH) specializing in XCyting DNA fluorescence probes for FISH and molecular diagnostics. The company is recognized for developing deep neural network-based imaging solutions, recently granted an EU patent for AI imaging technology. Products are marketed to forensic pathology, clinical cytology, and hematology laboratories. MetaSystems operates subsidiary offices and authorized distribution partners across major regions including USA, Latin America, Italy, India, China, Hong Kong, and Japan, with direct support teams in Germany.

Voiant is a clinical trial imaging Contract Research Organization (CRO) specializing in AI-powered imaging solutions for biopharmaceutical companies. With over 30 years of clinical expertise, Voiant delivers high-quality imaging endpoint data and endpoint adjudication services supporting therapies across oncology, ophthalmology, and respiratory indications from Phase I-IV global trials. The company operates a proprietary, purpose-built AI platform that accelerates imaging processing and analysis while maintaining scientific accuracy through expert human oversight. Voiant's services include independent reading center operations, blinded imaging review (BICR), and specialized imaging biomarker analysis. The company has expanded AI capabilities through acquisition of Voxeleron and maintains a global network of subspecialty-trained clinical readers, regulatory expertise, and over 2,700 registered clinical trial sites. Voiant has contributed to multiple FDA-approved therapies and serves as a trusted partner for sponsors, CROs, and clinical research organizations seeking reliable, reproducible imaging endpoint data and faster turnaround times.

BioView is a leading developer and manufacturer of automated cell imaging and analysis solutions for cytogenetics, oncology, and pathology laboratories. With nearly two decades of expertise, BioView specializes in diagnostic automation technology, particularly automated FISH (Fluorescence In Situ Hybridization) imaging and analysis. The company's comprehensive product portfolio includes the Cytogenetics Suite featuring automated karyotyping and FISH imaging platforms, as well as scanning systems ranging from manual workstations to fully automated loaders. BioView offers FDA-cleared and CE-marked applications for diverse diagnostics including hematology, prenatal testing, circulating tumor cell detection, and oncology applications. The company provides web-based analysis tools enabling case analysis and reporting from any location without software installation. BioView's systems are designed to enhance laboratory efficiency, accuracy, and standardization across diverse clinical and research workflows.

Lunit International Limited is a healthcare AI software company specializing in cancer detection and precision oncology. Founded in 2013 with headquarters in Seoul and offices in Boston, the company develops clinically validated, FDA-cleared AI solutions that enhance cancer screening and treatment optimization. Lunit's modular ecosystem integrates imaging analysis, digital pathology, and biomarker intelligence across radiology, pathology, and oncology workflows. The platform serves over 10,000 customer sites across 65+ countries, with deployments focused on early detection in breast cancer, lung cancer, and personalized treatment selection through AI-powered biomarker analysis and immunohistochemistry quantification.

UltraSight is an Israeli digital health company specializing in AI-powered cardiac ultrasound imaging software. The platform provides real-time guidance and quality assessment to enable healthcare professionals of any sonography proficiency level to consistently perform high-quality cardiac ultrasound acquisitions at the point of care—in clinics, community hospitals, ambulances, and remote/rural areas. The software integrates with ultrasound devices (including Philips Lumify) and complies with healthcare standards (HL7, DICOM). UltraSight has achieved FDA clearance and CE Mark certification. The solution addresses critical clinical needs in emergency medicine, out-of-hospital care, critical care monitoring, and resource-limited settings, democratizing access to cardiac imaging while improving diagnostic accuracy and reducing repeat procedures. Clinical evidence demonstrates that novice users achieve diagnostic-quality images approaching expert sonographer performance following minimal training.

PaxeraHealth is a Boston-based enterprise medical imaging software company specializing in AI-driven imaging platforms and solutions. The company develops advanced Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and vendor-neutral archive (VNA) platforms designed for healthcare providers globally. PaxeraHealth's core portfolio includes PaxeraUltimaAI—an AI-assisted enterprise imaging platform with native diagnostic algorithms to enhance workflow efficiency and reporting speed; ARK—a no-code imaging algorithm platform enabling users to develop multimodal AI algorithms without coding expertise; and VNAi—a data warehouse imaging platform providing secure, vendor-neutral control of imaging data with advanced lifecycle management. The company serves over 1,500 healthcare customers across 45 countries, managing 220+ million imaging studies annually. PaxeraHealth's solutions emphasize workflow automation, diagnostic accuracy improvement, clinical decision support, and seamless interoperability with existing EMR and PACS systems. The company employs approximately 106 people from 12 countries and maintains regional offices and a global distributor network to support healthcare systems of all sizes.

Elucid Bioimaging develops FDA-cleared cardiovascular imaging analytics software specializing in quantitative plaque assessment from coronary CT angiography (CCTA). The company's flagship product, PlaqueIQ™, employs CT Virtual Histology™ technology to characterize arterial plaque composition non-invasively, leveraging algorithms trained and validated against ground-truth histopathology. PlaqueIQ quantifies and classifies plaque morphology into calcified, non-calcified matrix, and lipid-rich necrotic core (LRNC) components, delivering patient-, vessel-, and lesion-level analysis with high correlation to ex vivo histology (r=0.87–0.99 across plaque types). The software integrates into clinical PACS workflows via DICOM-wrapped PDFs and interactive browser-based reports, enabling physicians to assess coronary and carotid atherosclerosis risk and guide medical versus interventional treatment decisions. Elucid holds FDA 510(k) clearance (K183012, December 2018) and has achieved Category I CPT coding and broad CMS reimbursement as of January 2026. The company also develops FFRCT (fractional flow reserve CT) technology under regulatory pathway. Served markets include cardiology, interventional cardiology, radiology, and cardiovascular research. Clinical validation includes partnership with CVPath Institute and peer-reviewed publications in major cardiovascular literature.

Fortis Life Sciences is a strategic platform company based in Waltham, Massachusetts, founded in August 2020. It operates as a multi-subsidiary life sciences tools provider delivering specialized reagents, diagnostic components, and custom development services to biopharma, diagnostics, and research organizations globally. The company integrates five ISO 13485 certified and GMP-compliant North American manufacturing and R&D locations under its "Farm-to-Bench" system, spanning antibody discovery and production, viral vector manufacturing, nanoparticle synthesis, molecular biology reagents, and diagnostic component CDMO services. Core product portfolio includes premium monoclonal and recombinant antibodies (validated for ELISA, Western blot, IHC, flow cytometry, spatial biology), VHH domain libraries (AbNano platform), lateral flow immunoassay components, assay-grade enzymes and master mixes, diagnostic grade nanoparticles (gold, platinum, silica), and lentiviral and AAV vector production. The company also offers contract manufacturing, antibody development, spatial biology imaging services, and precision lyophilization for stable diagnostic products. It serves over 10,000 customers across biopharma, diagnostics OEMs, contract manufacturers, academic research, and applied technology sectors.

OnPoint Surgical is a medical technology company specializing in augmented reality (AR) and artificial intelligence (AI) guidance for spinal surgery. The company's flagship product, the OnPoint AR Spine System, received FDA 510(k) clearance in September 2023. The system uses a lightweight head-mounted display (under 4 ounces, 4K resolution) to project virtual surgical guides and 3D anatomical landmarks directly onto the surgeon's visual field during procedures. Key capabilities include real-time surgical planning, virtual implant visualization, and intraoperative decision support for pedicle and cortical screw placement, lumbar interbody cage positioning, and cervical spine procedures. The platform is vendor-agnostic, compatible with implants and instruments from all major manufacturers, and integrates seamlessly into existing surgical workflows without requiring technique modifications. OnPoint AR preserves tactile feedback—a critical advantage over robotic systems—while reducing setup time to under 5 minutes and potentially decreasing OR time by approximately 20 minutes through pre-operative CT planning.

Qynapse is a medical software company specializing in AI-powered neuroimaging analysis for central nervous system (CNS) diseases. The company develops advanced algorithms and software platforms that analyze MRI brain scans to provide automated biomarkers, diagnostic support, and disease monitoring capabilities for conditions including Alzheimer's disease, multiple sclerosis, and Parkinson's disease. QyScore® is Qynapse's flagship FDA-cleared (Class II) and CE-marked (Class IIa) software product designed for automatic labeling, visualization, and volumetric quantification of brain structures and lesions from MR images. The software provides volumetric data compared to reference percentile datasets and is intended to support clinicians in CNS disease diagnosis and monitoring. QyPredict® is a research-use-only platform combining genomics, biofluids, neuroimaging, cognitive endpoints, and activity measures to assess CNS disease trajectory. Qynapse addresses a critical clinical need: current CNS disease misdiagnosis rates reach approximately 30%, and the company reports diagnostic accuracy improvement from 66–70% to over 90%. The company serves healthcare providers, pharmaceutical researchers, payers, and patients/caregivers. Products are built on proprietary technology incorporating 20 algorithms and the company's proprietary normative dataset of over 10,000 brain scan images. Regulatory approvals include FDA clearance and CE marking; expansion into additional global markets is underway. The company's clinical advisory board includes leading neurology and radiology experts.

CellTivity Scientific is a medical technology company specializing in live-cell imaging platforms for real-time assessment of cellular behavior, morphology, and metabolic activity. The flagship Van Gogh Microscopy System utilizes proprietary Dynamic Cell Imaging (DCI) technology to provide non-invasive visualization of metabolic activity and tissue adequacy during biopsies. The system enables proceduralists to identify cell types—including cancer cells, immune cells, and granuloma—and assess biopsy sample quality in real time, improving diagnostic yield and reducing biopsy inadequacy. Applications span interventional pulmonology, thoracic procedures, bronchoscopy, and general tissue sampling across oncology specialties. The company offers CE-registered devices with deployment, training, and pathology integration support to hospitals and clinics, targeting enhanced point-of-care diagnostics and streamlined collaboration with pathology departments.